This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Digging into the results from the phase 3 study of VX-548 for the treatment of acute pain
Ticker(s): VRTXWho's the expert?
Institution: Vanderbilt University
- Interventional pain medicine physician at Vanderbilt University Medical Center
- Co-director of the Vanderbilt Center for Neuromodulation who implants spinal stimulators for 8-10 diabetic retinopathy patients a month
Interview GoalThis interview will focus on the potential of Vertex Pharmaceuticals VX-548, a non-opioid drug, shown to reduce nerve pain in a recent Phase 3 Program for the treatment of Moderate-to-Severe Acute Pain.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
